Clinical trial · Observational
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)
NCT07413757CI-TRIAL-00125472CHOICErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Physicians group
- description
- Physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI.
- label
- Patinet group
- description
- Patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC
Primary outcomes (2)
- measure
- Preferences weights for each attribute level evaluated in the DCE
- timeFrame
- Day of interview/survey completion(Day1)
- description
- Preference weights will be estimated for each attribute level included in the DCE where a more positive preference weight indicates a stronger preference for the attribute level. The preference weights allow for comparison for relative preference for levels within the same attribute.
- measure
- Relative attribute importance (RAI)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: The following inclusion criteria must be met in order to be enrolled in the stage 1: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter Physician: * Provide informed consent * Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals * Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month * Holding the title of associate chief physician or higher The following inclusion criteria must be met in order to be enrolled in the stage 2: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter Physician: * Provide informed consent * Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals * Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month * Holding the title of attending physician or higher Exclusion Criteria: Not applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.